Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation

Bone Marrow Transplantation

Volumn 20, Issue 10, 1997, Pages 859-863

  Tsai, T ^a   Goodman, S ^b   Saez, R ^c   Schiller, G ^d   Adkins, D ^e   Callander, N ^a   Wolff, S ^b   Freytes, C O ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BMT; Leukemia; Lymphoma; Relapse; Second transplant

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOMA; MALE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0030730465     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700989     Document Type: Article

References (16)

1. Vose JM, Biernian PJ, Anderson JR et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142-2148.
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
4. Keith MS. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Cambridge, 1994, pp 339-362.
5. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
6. Weaver CH, Appelbaum FR, Petersen FB et al. Follow-up report on the outcome of patients relapsing after autologous marrow transplantation for malignant lymphoma (letter). J Clin Oncol 1993; 11: 812-813.
7. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
8. Chopra R, Goldstone AH, Pearce R et al. Autologous vs allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690-1695.
9. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-1347.
10. Gajewski J, Phillips G, Sobocinski K et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
11. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/-cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193-1199.
12. Reece DE, Barnett MJ, Shepherd JD et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/-P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after chemotherapy. Blood 1995; 86: 451-456.
13. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996; 14: 1291-1296.
14. Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39-42.
15. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in bone marrow transplant patients. Blood 1990; 76: 2462-2465.
16. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Donor leukocyte infusions for molecular or cytogenetic relapse of CML following allogeneic BMT: graft-versus-leukemia responses with minimal toxicity. Blood 1995; 86: 10 (Abstr. 2251).